Clinical Utility of the Prostate Health Index (Phi) for Biopsy Decision Management in a Large Group Urology Practice Setting

Prostate Cancer and Prostatic Diseases - United Kingdom
doi 10.1038/s41391-017-0008-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Leveraging the Utility of Pharmacogenomics in Psychiatry Through Clinical Decision Support: A Focus Group Study

Annals of General Psychiatry
PsychiatryMental Health
2019English

The Utility of Prostate-Specific Antigen Velocity Thresholds in Clinical Practice: A Population-Based Analysis

BJU International
Urology
2008English

Assessment on Clinical Value of Prostate Health Index in the Diagnosis of Prostate Cancer

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Adaptive Semi-Supervised Consensus Model for Multi-Criteria Large Group Decision Making in a Linguistic Setting

2017English

Future Aspects of Prostate Biopsy – The Use of Primary Circulating Prostate Cells to Select Patients for Prostate Biopsy: Evidence, Utility and Cost-Benefit

2011English

Management of Patients Treated With Pertuzumab in the Australian Clinical Practice Setting

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2016English

Clinical Utility and Cost Modelling of the Phi Test to Triage Referrals Into Image-Based Diagnostic Services for Suspected Prostate Cancer: The PRIM (Phi to RefIne Mri) Study

BMC Medicine
Medicine
2020English

The Prostate Health Index

Urologic Clinics of North America
Urology
2016English

Variations in Prostate Biopsy Practice: A Quantitative Questionnaire-Based Study

Canadian Urological Association Journal
Urology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy